Cite
MLA Citation
Cosimo Bruni et al.. “Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis.” Therapeutic advances in musculoskeletal disease, vol. 13, 2021, p. . http://access.bl.uk/ark:/81055/vdc_100141093846.0x0000cf